Hi Jill,
I was diagnosed HER2/ER/PR positive and put on tamoxifen in 2002, but as time went by I found questions had been raised as early as 1998 about using it routinely for HER2/hormone receptor positive patients. I was taken off tamoxifen upon further discussion with my oncologist. Here is an article from 2004 that discusses just
one of a number of questions about tamoxifen and HER2's that is fairly easily understood:
http://www.oncolink.org/resources/ar...h=06&year=2004
Here is a more recent discussion:
http://edrv.endojournals.org/cgi/con...tract/29/2/217
At this point, as patients we are not identified for risk by testing (for example) for AIB1 levels, so how would an oncologist have the information to decide which patients should have the tamoxifen and which ones should not? Might it be safer for premeno HER2's to avoid using tamoxifen, at least until ways to deal with the problem of development of resistance are provided to such patients, rather than encouraging them to use it?
AlaskaAngel